For patients with NF2-related schwannomatosis and progressive tumors, the ALK inhibitor brigatinib (Alunbrig) was associated with radiographic response for multiple tumor types, as well as ...
Bevacizumab treatment at 7.5 mg/kg every 3 weeks results in improved hearing in approximately 35%-40% of patients with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas (VSs).
Patients with a genetic syndrome called NF2-related schwannomatosis (NF2-SWN) have tumors that develop on the covering of the brain or grow along the nerves in the brain, spinal cord, and/or other ...
On the occasion of World NF2 Awareness Day, the Children's Tumor Foundation has announced the establishment of a significant research initiative dedicated to finding effective treatments for NF2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback